160 related articles for article (PubMed ID: 17962184)
1. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.
Domaoal RA; McMahon M; Thio CL; Bailey CM; Tirado-Rives J; Obikhod A; Detorio M; Rapp KL; Siliciano RF; Schinazi RF; Anderson KS
J Biol Chem; 2008 Feb; 283(9):5452-9. PubMed ID: 17962184
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
5. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
[TBL] [Abstract][Full Text] [Related]
6. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
[TBL] [Abstract][Full Text] [Related]
7. The HBV drug entecavir - effects on HIV-1 replication and resistance.
McMahon MA; Jilek BL; Brennan TP; Shen L; Zhou Y; Wind-Rotolo M; Xing S; Bhat S; Hale B; Hegarty R; Chong CR; Liu JO; Siliciano RF; Thio CL
N Engl J Med; 2007 Jun; 356(25):2614-21. PubMed ID: 17582071
[TBL] [Abstract][Full Text] [Related]
8. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
[TBL] [Abstract][Full Text] [Related]
9. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatitis B virus polymerase by entecavir.
Langley DR; Walsh AW; Baldick CJ; Eggers BJ; Rose RE; Levine SM; Kapur AJ; Colonno RJ; Tenney DJ
J Virol; 2007 Apr; 81(8):3992-4001. PubMed ID: 17267485
[TBL] [Abstract][Full Text] [Related]
11. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
[TBL] [Abstract][Full Text] [Related]
12. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
Sasadeusz J; Audsley J; Mijch A; Baden R; Caro J; Hunter H; Matthews G; McMahon MA; Olender SA; Siliciano RF; Lewin SR; Thio CL
AIDS; 2008 May; 22(8):947-55. PubMed ID: 18453854
[TBL] [Abstract][Full Text] [Related]
13. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
14. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
15. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.
Xu HT; Asahchop EL; Oliveira M; Quashie PK; Quan Y; Brenner BG; Wainberg MA
J Virol; 2011 Nov; 85(21):11300-8. PubMed ID: 21849444
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Rawal RK; Konreddy AK; Chu CK
Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
[TBL] [Abstract][Full Text] [Related]
17. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
18. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.
Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
J Biol Chem; 2008 Dec; 283(49):34218-28. PubMed ID: 18940786
[TBL] [Abstract][Full Text] [Related]
19. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
[TBL] [Abstract][Full Text] [Related]
20. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
